SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive long-term follow-up data from the pivotal, Phase III ...

High TILs may predict which patients with early HER2-positive breast cancer may have a reduced risk for disease relapse or death with Herceptin treatment. High tumor infiltrating lymphocytes (TILs) in ...

B ERLIN -- The antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) delivered impressive results in ...

Neoadjuvant Enhertu then THP improved pathological complete response rate in patients with high-risk, HER2-positive early ...

– At three years, 88.3 percent of people treated with Kadcyla in the adjuvant HER2-positive early breast cancer setting did not have their breast cancer return compared to 77.0 percent treated with ...

This is the gap that has been flagged by the latest Lancet study, which shows that compared to high income countries, where ...

Teva Pharmaceuticals International said Monday that Prestige received marketing authorization last year from the European Commission for Tuznue, a biosimilar to Herceptin approved for the treatment of ...

Trastuzumab rezetecan significantly improves progression-free survival in HER2-positive breast cancer, outperforming standard treatments in a pivotal trial.

Teva and Prestige announce a license and supply agreement for the commercialization of Prestige’s Tuznue ® , a biosimilar to Herceptin ® ...

Shanghai Henlius Biotech’s partner, Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, has received permission from the Food and Drug Administration for Hercessi (HLX02, ...

Sept. 1, 2005 — The U.S. Food and Drug Administration (FDA) and Genentech, Inc., have warned healthcare professionals via letter of study data linking trastuzumab (Herceptin) therapy to a ...